Clinical trials
catalyst calendar across sponsors →Studies where ELDN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 8 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, +3 more) · FINRA short interest 6.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant RecipientsNCT06126380Safety and Tolerability - Incidence of Treatment Emergent Adverse EventsNon-randomized · Open-label · Treatment | Phase 2 | Enrolling by invitation | Drug: AT-1501, Tacrolimus | Kidney Transplant Rejection | 132 | Dec 2029 | ≤ 1,230 d | 2025-12-10 |
| Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney TransplantNCT05027906Safety IncidencesOpen-label · Treatment | Phase 1/2 | Recruiting | Drug: AT-1501 | Prevention of Rejection in Kidney Transplant | 48 | Jan 2027 | ≤ 165 d | 2025-06-29 |
| Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney TransplantationNCT05983770eGFR at 12 monthsRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: AT-1501, Tacrolimus | Kidney Transplant Rejection | 127 | 2025-09-11actual | — | 2026-07-22 |
| Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1DNCT05480657Safety - Adverse Events (AE) and Adverse Events of Special Interest (AEoSI)Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Study withdrawn | Biological: AT-1501 IV Infusion, Isolated cadaveric islet cells | Brittle Type 1 Diabetes Mellitus | 0 | Aug 2024 | — | 2023-01-18 |
| Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)NCT05125068Efficacy - change in participants UPCRNon-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: An administrative decision was made to terminate the AT-1501-N205 study. This voluntary business-related decision was not related to the safety of tegoprubart (AT-1501). Available safety data demonstrated tegoprubart to be safe and well tolerated. | Drug: AT-1501 | IgA Nephropathy, IgAN | 24 | 2023-07-31actual | — | 2024-03-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19